Anti Cldn4/Anti Cd137 Bispecific Antibody

< Back

Anti Cldn4/Anti Cd137 Bispecific Antibody

Abstract: The present invention addresses the problem of providing an anti-CLDN4/anti-CD137 bispecific antibody that can be used in treating cancer. This anti-CLDN4/anti-CD137 bispecific antibody, which is manufactured using an anti-CLDN4 antibody that binds to CLDN4 and an anti-CD137 antibody that binds to CD137, has an agonist action against CD137, promotes interferon-? production in T-cells, and demonstrates cytotoxic activity against cancer cells expressing CLDN4 on the cell surface. Furthermore, this anti-CLDN4/anti-CD137 bispecific antibody was able to be safely administered to monkeys. Accordingly, this anti-CLDN4/anti-CD137 bispecific antibody can be used to treat cancer in humans.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #

Filing Date

14 November 2023

Publication Number

51/2023

Publication Type

INA

Invention Field

BIOTECHNOLOGY

Status

Email

Parent Application

Applicants

ASTELLAS PHARMA INC.

5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

NATIONAL CANCER CENTER

1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 1040045

Inventors

1. TENDA, Yoshiyuki

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

2. YURI, Masatoshi

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

3. YAGI, Shigenori

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

4. SATAKE, Yoshiki

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

5. HIRAYAMA, Kazunori

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

6. SHIRAI, Hiroki

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

7. SASAKI, Hiroki

c/o National Cancer Center, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 1040045

8. CHIWAKI, Fumiko

c/o National Cancer Center, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 1040045

9. KOMATSU, Masayuki

c/o National Cancer Center, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 1040045

Specification

Documents

Application Documents

#	Name	Date
1	202347077414-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [14-11-2023(online)].pdf	2023-11-14
2	202347077414-STATEMENT OF UNDERTAKING (FORM 3) [14-11-2023(online)].pdf	2023-11-14
3	202347077414-Sequence Listing in txt [14-11-2023(online)].txt	2023-11-14
4	202347077414-Sequence Listing in PDF [14-11-2023(online)].pdf	2023-11-14
5	202347077414-PROOF OF RIGHT [14-11-2023(online)].pdf	2023-11-14
6	202347077414-PRIORITY DOCUMENTS [14-11-2023(online)].pdf	2023-11-14
7	202347077414-FORM 1 [14-11-2023(online)].pdf	2023-11-14
8	202347077414-DRAWINGS [14-11-2023(online)].pdf	2023-11-14
9	202347077414-DECLARATION OF INVENTORSHIP (FORM 5) [14-11-2023(online)].pdf	2023-11-14
10	202347077414-COMPLETE SPECIFICATION [14-11-2023(online)].pdf	2023-11-14
11	202347077414-FORM-26 [22-11-2023(online)].pdf	2023-11-22
12	202347077414-FORM 3 [29-04-2024(online)].pdf	2024-04-29
13	202347077414-FORM 18 [26-11-2024(online)].pdf	2024-11-26